Orion Oyj (Orion Oyj) 5-Year EBITDA Growth Rate : 5.20% (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Orion Oyj 5-Year EBITDA Growth Rate?

Orion Oyj's EBITDA per Share for the three months ended in Mar. 2024 was $0.22.

During the past 12 months, Orion Oyj's average EBITDA Per Share Growth Rate was -34.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -0.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 5.20% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Orion Oyj was 31.70% per year. The lowest was -4.60% per year. And the median was 1.10% per year.

Competitive Comparison of Orion Oyj's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Orion Oyj's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orion Oyj's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Orion Oyj's 5-Year EBITDA Growth Rate falls into.

Orion Oyj 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Orion Oyj (OTCPK:ORINY) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Orion Oyj 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Orion Oyj's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Orion Oyj (Orion Oyj) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Orion Oyj (OTCPK:ORINY) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

1ORNBV:Italy ORNBVh:UK 0M2O:UK ORNBV:Finland ORNAV:Finland OFK:Germany

Address

Orionintie 1, P.O. Box 65, Espoo, FIN, FI-02200

Website

https://www.orion.fi

Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company primarily focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. Orion mainly serves Finland but also has a presence in other European countries and North America.

Orion Oyj (Orion Oyj) Headlines

From GuruFocus

Q4 2023 Orion Oyj Earnings Call Transcript

By GuruFocus Research • 02-14-2024